Gentian Diagnostics ASA (OSL:GENT)

Market Cap	842.06M
Revenue (ttm)	172.52M
Net Income (ttm)	42.78M
Shares Out	15.42M
EPS (ttm)	2.75
PE Ratio	19.85
Forward PE	53.01
Dividend	0.40 (0.73%)
Ex-Dividend Date	n/a

Volume	5,099
Average Volume	11,959
Open	54.00
Previous Close	54.60
Day's Range	53.80 - 56.00
52-Week Range	37.00 - 65.80
Beta	0.39
RSI	49.41
Earnings Date	Feb 11, 2026

About Gentian Diagnostics ASA

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chro...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 63
• Stock Exchange: Oslo Børs
• Ticker Symbol: GENT